Recruiting
Phase 3

KN3835

Sponsor:

Endo USA Inc., a Keenova Therapeutics Company

Code:

NCT07846280

Conditions

Flexible Hammertoe

Semi-flexible Hammertoe

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

KN3835

Study Details

Brief summary:

The primary purpose of this study is to assess the long-term safety of treatment and retreatment with KN3835 for flexible/semi-flexible HMT.

Conditions

Flexible Hammertoe

Semi-flexible Hammertoe

Study ID

NCT07846280

Start date

Oct 15, 2026

Status verified date

Nov, 2026

Completion date

Dec, 2028

Anticipated

Primary completion date

Dec, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Were enrolled in and completed Study KN3835-313 (participants who completed the study are those that completed the Day 57/End of Study Visit, were assessed for safety, and received at least 1 dose of study intervention).
  • Has no significant medical history or examination findings related to the foot to be treated, which in the investigator's opinion, would make the participant unsuitable for study intervention administration or study required evaluations.
  • If female, be of non-childbearing potential or, if of childbearing potential, be non-pregnant, non-lactating and agree to use effective contraception when with a male partner for the duration of the study and for 28 days after treatment.
  • Be willing and able to comply with all protocol required visits and assessments.

Key Exclusion Criteria:

  • Has any significant medical condition, or a serious or severe event in the parent study or any ongoing event from the parent study, which in the investigator's opinion, would make the participant unsuitable for enrollment in the study.
  • Has received or plans to receive surgical or nonsurgical treatments on the foot or toe that was treated for the duration of study participation.

Note: Other inclusion/exclusion criteria may apply.

Study Design

Enrollment

470 participants

Anticipated

Allocation

Non randomized

Intervention Model

Sequential

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Observation then KN3835

After observation during Part 1 of the study, participants will have the option to receive treatment or retreatment with KN3835 in Part 2.

no intervention: Observation Only

Participants will be observed through Part 1. After completion of Part 1, participants will have the option to be observed only during Part 2 of the study.

Interventions

KN3835

Participants will receive KN3835 in Part 2 of the Study

Primary outcome measure

  • Number of Participants with Adverse Events [ Time Frame: Observational Day 1 up to Treatment/Retreatment Period Day 360 ]

Central Contacts and Locations

Central contacts

Locations

Keenova Site-008

Recruiting

Tarzana, California, United States, 91356

Principal Investigator:

Fardin Hakakian

Keenova Site-004

Recruiting

Pinellas Park, Florida, United States, 33782

Principal Investigator:

Jason Levy

Keenova Site-007

Recruiting

Sweetwater, Florida, United States, 33172

Principal Investigator:

Edward Gonzalez

Keenova Site-006

Recruiting

Salt Lake City, Utah, United States, 84107

Principal Investigator:

Clark Larsen

More Information

Sponsor

Endo USA Inc., a Keenova Therapeutics Company

Last update posted

Nov 16, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-17. This information was provided to ClinicalTrials.gov by Endo USA Inc., a Keenova Therapeutics Company on 2026-11-16. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.